CardioFocus, Inc. today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight® X3 Endoscopic Ablation System. The revolutionary cardiac ablation technology is designed to treat drug refractory, symptomatic paroxysmal atrial fibrillation (AFib), the most common heart rhythm disorder.
The HeartLight Excalibur Balloon™ used with the new HeartLight® X3 System.
Henry D. Huang, M.D., FACC, FHRS of Rush University Medical Center in Chicago, and David Kenigsberg M.D., FACC, FHRS of Westside Regional Medical Center in Plantation, Florida performed the first procedures using the X3 System.
“We are dedicated to providing our patients the most efficacious and innovative treatment options for AFib, a common but treatable heart condition,” Dr. Huang said. “As the initial medical center in the U.S. to offer the HeartLight X3 System, we look forward to being able to provide effective symptom relief for Chicago-area patients safely, confidently and quicker than ever before. We are excited by the results we’ve seen thus far, which build upon the positive outcomes we experienced in treating more than 100 patients with previous versions of HeartLight.”
More than 2.3 million people in the U.S. suffer from AFib, and the numbers are climbing along with the aging population1. By 2050, AFib is expected to affect 15.9 million people2.
“Early on, I recognized the potential of the HeartLight System and after using it to treat more than 40 patients, I have been eager to offer the next-generation, HeartLight X3, to our patients here in South Florida,” said Dr. Kenigsberg. “I believe the technology has true game-changing potential in how it facilitates pulmonary vein isolation (PVI).”
The HeartLight X3 System received U.S. Food and Drug Administration (FDA) approval for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF) in May. Approval was based on a comprehensive submission, including outcomes from the study of 60 HeartLight X3 patients over 12 months. All study endpoints were achieved, and the device achieved very rapid PVI, in as few as three minutes for a single pulmonary vein.
“Following the impressive clinical trial results of HeartLight X3, we have been equally encouraged by these initial real-world patient experiences,” said Burke T. Barrett, Chief Executive Officer at CardioFocus. “Following the swift FDA approval, we are pleased to have begun a focused commercial rollout of the HeartLight X3 system in the U.S. that will showcase its impressive array of features.”
Written by: CardioFocus
Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.